Literature DB >> 29316361

Effects of serum, enzyme, thiol, and forced degradation on the stabilities of αO-Conotoxin GeXIVA[1,2] and GeXIVA [1,4].

Shurun Yu1,2,3, Yong Wu1,2, Pan Xu1,2,3, Shuai Wang1,2,3, Dongting Zhangsun1,2, Sulan Luo1,2.   

Abstract

αO-conotoxin GeXIVA, which is a potent antagonist of α9α10 nicotinic acetylcholine receptor (nAChR), is of great interest as a potential analgesic for chronic neuropathic pain. It has three isomers, of which both GeXIVA[1,2] and GeXIVA[1,4] showed similar low nanomolar IC50 s in potent blocking rat α9α10 nAChRs. Here, we first reported stabilities of GeXIVA[1,2] and GeXIVA[1,4] in various biochemical circumstances, including human serum, enzymatic degradation, and thiol, which would be the key factors to affect stabilities of the two isomers in vivo. Simultaneously, forced degradation was carried out to evaluate stabilities of the two isomers. GeXIVA[1,2] and GeXIVA[1,4] were unstable when they were incubated in serum and digestive enzymes at 37°C. Their disulfide bond frameworks were easy to be scrambled in GSH and HSA. For different stress conditions, their stabilities were impacted greatly by oxidation, temperature, and alkaline conditions. The results may provide a foundation for storage conditions, structural modification, and pharmaceutical preparation of GeXIVA[1,2] and GeXIVA[1,4].
© 2018 John Wiley & Sons A/S.

Entities:  

Keywords:  enzymatic degradation; forced degradation; serum; stabilities; thiol; αO-conotoxin GeXIVA[1,2] and GeXIVA[1, 4]

Mesh:

Substances:

Year:  2018        PMID: 29316361     DOI: 10.1111/cbdd.13167

Source DB:  PubMed          Journal:  Chem Biol Drug Des        ISSN: 1747-0277            Impact factor:   2.817


  3 in total

1.  αO-Conotoxin GeXIVA Inhibits the Growth of Breast Cancer Cells via Interaction with α9 Nicotine Acetylcholine Receptors.

Authors:  Zhihua Sun; Jiaolin Bao; Manqi Zhangsun; Shuai Dong; Dongting Zhangsun; Sulan Luo
Journal:  Mar Drugs       Date:  2020-04-07       Impact factor: 5.118

2.  Lyophilization Serves as an Effective Strategy for Drug Development of the α9α10 Nicotinic Acetylcholine Receptor Antagonist α-Conotoxin GeXIVA[1,2].

Authors:  Zhiguo Li; Xiaolu Han; Xiaoxuan Hong; Xianfu Li; Jing Gao; Hui Zhang; Aiping Zheng
Journal:  Mar Drugs       Date:  2021-02-25       Impact factor: 5.118

3.  Preparation of uniform-sized GeXIVA[1,2]-loaded PLGA microspheres as long-effective release system with high encapsulation efficiency.

Authors:  Lu Li; Zhiguo Li; Yongxin Guo; Kai Zhang; Weidong Mi; Jing Liu
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.